Sands Capital Alternatives, LLC reported 24 positions worth $613.55M for the quarter ended Jun 30, 2026, up 45.7% on the prior quarter. It opened 3 new positions, added to 10, trimmed 2 and exited 0. Its largest holding is Alamar Biosciences, Inc. at 18.7% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ALMR Alamar Biosciences, Inc. | +4.23M | – | $114.62M | 18.68% |
| ODTX Odyssey Therapeutics, Inc. | +875.0K | – | $16.37M | 2.67% |
| NU Nu Holdings Ltd. | +557.2K | +8.5% | $7.44M | 15.45% |
| CBRS Cerebras Systems Inc. | +32.8K | – | $7.25M | 1.18% |
| CPNG Coupang, Inc. | +317.2K | +31.3% | $5.51M | 3.76% |
| KVYO Klaviyo, Inc. | +278.5K | +7.6% | $4.20M | 9.67% |
| DASH DoorDash, Inc. | +16.3K | +14.7% | $3.01M | 3.84% |
| TOST Toast, Inc. | +63.2K | +21.0% | $1.76M | 1.65% |
| TTAN ServiceTitan, Inc. | +18.7K | +20.8% | $1.32M | 1.25% |
| SNOW Snowflake Inc. | +4,245 | +21.0% | $1.08M | 1.02% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALMR Alamar Biosciences, Inc. | Healthcare | 4.23M | $114.62M | 18.68% | +4.23M | – | New | 6.1% |
| 2 | NU Nu Holdings Ltd. | Financial Services | 7.09M | $94.79M | 15.45% | +557.2K | +8.5% | Added | 0.15% |
| 3 | KVYO Klaviyo, Inc. | Technology | 3.93M | $59.32M | 9.67% | +278.5K | +7.6% | Added | 2.99% |
| 4 | BBNX Beta Bionics, Inc. | Healthcare | 3.71M | $58.11M | 9.47% | 0 | 0.0% | Unchanged | 8.32% |
| 5 | SGP SpyGlass Pharma, Inc. | Healthcare | 2.50M | $55.65M | 9.07% | 0 | 0.0% | Unchanged | 7.47% |
| 6 | IKT Inhibikase Therapeutics, Inc. | Healthcare | 13.02M | $26.43M | 4.31% | 0 | 0.0% | Unchanged | 7.46% |
| 7 | DASH DoorDash, Inc. | Technology | 127.6K | $23.54M | 3.84% | +16.3K | +14.7% | Added | 0.03% |
| 8 | CPNG Coupang, Inc. | Consumer Discretionary | 1.33M | $23.09M | 3.76% | +317.2K | +31.3% | Added | 0.08% |
| 9 | DDOG Datadog, Inc. | Technology | 80.9K | $21.05M | 3.43% | -4,942 | -5.8% | Reduced | 0.02% |
| 10 | BIOA BioAge Labs, Inc. | Healthcare | 786.4K | $19.27M | 3.14% | 0 | 0.0% | Unchanged | 1.72% |
| 11 | TXG 10x Genomics, Inc. | Healthcare | 481.8K | $18.47M | 3.01% | 0 | 0.0% | Unchanged | 0.37% |
| 12 | IOT Samsara Inc. | Technology | 515.7K | $16.72M | 2.73% | -44.6K | -8.0% | Reduced | 0.09% |
| 13 | ODTX Odyssey Therapeutics, Inc. | Healthcare | 875.0K | $16.37M | 2.67% | +875.0K | – | New | 1.83% |
| 14 | TOST Toast, Inc. | Technology | 364.9K | $10.15M | 1.65% | +63.2K | +21.0% | Added | 0.06% |
| 15 | ABOS Acumen Pharmaceuticals, Inc. | Healthcare | 3.72M | $9.93M | 1.62% | 0 | 0.0% | Unchanged | 5.14% |
Tip. Select a row to see that position’s full history at Sands Capital Alternatives.
As of its Q2 2026 13F filing, Sands Capital Alternatives, LLC’s five largest positions were Alamar Biosciences, Inc. (ALMR) at 18.7%, Nu Holdings Ltd. (NU) at 15.4%, Klaviyo, Inc. (KVYO) at 9.7%, Beta Bionics, Inc. (BBNX) at 9.5%, SpyGlass Pharma, Inc. (SGP) at 9.1% of the reported portfolio.
Sands Capital Alternatives, LLC reported a 13F portfolio worth $613.55M across 24 positions for Q2 2026. That is up 45.7% from the previous quarter.
Its largest purchases by value were Alamar Biosciences, Inc. ($114.62M), Odyssey Therapeutics, Inc. ($16.37M), Nu Holdings Ltd. ($7.44M). It opened 3 new positions.
Its largest sales by value were Samsara Inc. ($1.45M), Datadog, Inc. ($1.29M). It exited 0 positions entirely.
From the Form 13F-HR reports Sands Capital Alternatives, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.